Media headlines about Inovalon (NASDAQ:INOV) have been trending somewhat positive on Tuesday, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Inovalon earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned media coverage about the technology company an impact score of 45.295447660919 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Several research firms recently weighed in on INOV. BidaskClub lowered Inovalon from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 14th. KeyCorp reaffirmed a “hold” rating on shares of Inovalon in a research note on Tuesday, September 12th. ValuEngine raised Inovalon from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. Zacks Investment Research lowered Inovalon from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Finally, TheStreet raised Inovalon from a “d+” rating to a “c-” rating in a research note on Thursday, October 5th. Three equities research analysts have rated the stock with a sell rating and five have given a hold rating to the company’s stock. Inovalon currently has a consensus rating of “Hold” and a consensus price target of $12.00.

Inovalon (NASDAQ INOV) traded down $0.20 during trading hours on Tuesday, reaching $14.75. The company had a trading volume of 549,535 shares, compared to its average volume of 575,932. The firm has a market capitalization of $2,188.08, a price-to-earnings ratio of 71.43, a PEG ratio of 4.39 and a beta of 1.24. The company has a quick ratio of 5.62, a current ratio of 5.62 and a debt-to-equity ratio of 0.31. Inovalon has a fifty-two week low of $9.15 and a fifty-two week high of $17.80.

Inovalon (NASDAQ:INOV) last posted its earnings results on Wednesday, November 1st. The technology company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.08 by $0.01. The firm had revenue of $115.90 million during the quarter, compared to the consensus estimate of $114.79 million. Inovalon had a return on equity of 4.63% and a net margin of 4.07%. The business’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the company earned $0.10 earnings per share. sell-side analysts anticipate that Inovalon will post 0.24 EPS for the current fiscal year.

In other Inovalon news, President Robert A. Wychulis sold 85,828 shares of the stock in a transaction dated Tuesday, December 5th. The stock was sold at an average price of $15.54, for a total value of $1,333,767.12. Following the completion of the transaction, the president now directly owns 466,286 shares in the company, valued at $7,246,084.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Shauna L. Vernal sold 5,908 shares of the stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $16.01, for a total value of $94,587.08. Following the completion of the transaction, the insider now owns 47,309 shares of the company’s stock, valued at $757,417.09. The disclosure for this sale can be found here. 48.28% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at

Inovalon Company Profile

Inovalon Holdings, Inc (Inovalon) is a technology company. The Company provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models to the healthcare industry. Leveraging large-scale data interconnectivity capabilities, unparalleled proprietary data sets, advanced analytics, data-driven intervention systems, and subject matter expertise, Inovalon enables the assessment and improvement of clinical and quality outcomes and financial performance across the healthcare ecosystem.

Insider Buying and Selling by Quarter for Inovalon (NASDAQ:INOV)

Receive News & Ratings for Inovalon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalon and related companies with's FREE daily email newsletter.